Endonasal Dacryocystorhinostomy for Nasolacrimal Duct Obstruction in Patients with Sarcoidosis

被引:12
作者
Avisar, Inbal [1 ]
McNab, Alan A. [2 ]
Dolman, Peter J. [3 ]
Patel, Bhupendra [4 ]
DeSousa, Jean-Louis [5 ]
Selva, Dinesh [6 ]
Malhotra, Raman [1 ]
机构
[1] Queen Victoria Hosp, Corneoplast Unit, E Grinstead, England
[2] Royal Victorian Eye & Ear Hosp, Ophthalm Plast & Lacrimal Clin, Melbourne, Vic, Australia
[3] Univ British Columbia, Eye Care Ctr, Dept Ophthalmol & Visual Sci, Vancouver, BC, Canada
[4] Univ Utah, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA
[5] Lions Eye Inst, Nedlands, WA, Australia
[6] Univ Adelaide, South Australian Inst Ophthalmol & Discipline Oph, Adelaide, SA, Australia
来源
ORBIT-AN INTERNATIONAL JOURNAL ON ORBITAL DISORDERS AND FACIAL RECONSTRUCTIVE SURGERY | 2013年 / 32卷 / 04期
关键词
Dacryocystorhinostomy; endonasal; nasolacrimal duct obstruction; sarcoidosis;
D O I
10.3109/01676830.2013.788670
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To evaluate the outcomes of endonasal dacryocystorhinostomy (EN-DCR) surgery in patients with sarcoidosis. Methods: Retrospective chart review of all patients with sarcoidosis undergoing EN-DCR in 6 practices from 1999-2011. Results: We included 18 procedures in 14 patients (8 female, 6 male) who underwent EN-DCR for acquired NLDO secondary to sarcoidosis. The mean age was 53.7 (range 38-82). The presenting symptom in all cases was epiphora. Eight patients (57%) complained of having additional nasal congestion. Surgery was performed using endoscopic powered-type DCR with flaps in 12/18 (67%) and non-endoscopic mechanical EN-DCR in 6/18 (33%). In 15 (83%) cases the lacrimal sac and nasal mucosa appeared abnormally yellowish, crusty, oedematous and friable. Five patients were treated with pre-operative oral steroid and overall 8 patients had oral prednisolone post operatively, 30-60mg tapered within 10 days-8 weeks. One patient had difficulties in tapering down the oral steroids at 6 months of follow-up. All patients were free of epiphora and patent to syringing, with nasal endoscopy revealing free flow of fluorescein through the ostium at a mean follow-up of 11.3 months (median follow-up 9 months). Conclusions: All 18 cases of acquired nasolacrimal duct obstruction secondary to sarcoidosis were treated successfully with EN-DCR. An abnormal appearance of the nasal mucosa is an important sign. Nasal congestion is a frequent sign. A successful outcome may not depend on intensive long-term therapy with local or systemic steroids. Mechanical or powered EN-DCR for nasolacrimal duct obstruction secondary to sarcoidosis achieves encouraging medium-term outcomes.
引用
收藏
页码:225 / 230
页数:6
相关论文
共 31 条
[21]   Medical progress - Sarcoidosis [J].
Newman, LS ;
Rose, CS ;
Maier, LA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (17) :1224-1234
[22]   SARCOIDOSIS AND ITS OPHTHALMIC MANIFESTATIONS [J].
OBENAUF, CD ;
SHAW, HE ;
SYDNOR, CF ;
KLINTWORTH, GK .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1978, 86 (05) :648-655
[23]   Early Experience Using a New Modified Bone Nibbler for Superior Osteotomy During Endonasal Dacryocystorhinostomy [J].
Patel, Vikesh ;
Ross, Jonathan J. ;
Malhotra, Raman .
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2011, 27 (01) :15-20
[24]   Orbital and adnexal sarcoidosis [J].
Prabhakaran, Venkatesh C. ;
Saeed, Perooz ;
Esmaeli, Bita ;
Sullivan, Timothy J. ;
McNab, Alan ;
Davis, Garry ;
Valenzuela, Alejandra ;
Leibovitch, Igal ;
Kesler, Anat ;
Sivak-Callcott, Jennifer ;
Hoyama, Erika ;
Selva, Dinesh .
ARCHIVES OF OPHTHALMOLOGY, 2007, 125 (12) :1657-1662
[25]  
Ramlee N, 2007, Singapore Med J, V48, pe168
[26]   Ocular involvement in sarcoidosis [J].
Rothova, A .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2000, 84 (01) :110-116
[27]   Mechanical endonasal dacryocystorhinostomy with mucosal flaps [J].
Tsirbas, A ;
Wormald, PJ .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2003, 87 (01) :43-47
[28]  
Vasquez R J, 1988, Ophthalmic Plast Reconstr Surg, V4, P147, DOI 10.1097/00002341-198804030-00005
[29]  
WEINGARTEN R, 1981, OPHTHALMIC SURG LAS, V12, P343
[30]  
WILSON R, 1988, EUR RESPIR J, V1, P269